Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

C. Leduc; B. Besse

doi:10.1093/annonc/mdu257

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

C. Leduc, B. Besse

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

3 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	2092
Nombre de pages	1
journal	Annals of Oncology
Volume	25
Numéro de publication	10
Les DOIs	https://doi.org/10.1093/annonc/mdu257
état	Publié - 1 oct. 2014

Accès au document

10.1093/annonc/mdu257

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d1569bcebb2e4f4dbf4db8480df7a27a,

title = "Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC",

author = "C. Leduc and B. Besse",

year = "2014",

month = oct,

day = "1",

doi = "10.1093/annonc/mdu257",

language = "English",

volume = "25",

pages = "2092",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "10",

}

TY - JOUR

T1 - Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

AU - Leduc, C.

AU - Besse, B.

PY - 2014/10/1

Y1 - 2014/10/1

UR - http://www.scopus.com/inward/record.url?scp=84930813084&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu257

DO - 10.1093/annonc/mdu257

M3 - Letter

C2 - 25035277

AN - SCOPUS:84930813084

SN - 0923-7534

VL - 25

SP - 2092

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -